- active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom - recruitingPHASE1, PHASE2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
This study is testing a new cancer medicine, AZD5335, on its own and with other treatments for various solid tumors. Researchers want to see if it's safe, tolerable, and if it can shrink tumors or stop them from growing. It's for people with advanced cancer.
United States · Australia · Canada - recruitingPHASE1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
This early-stage study is testing a new drug, MOMA-313, for advanced solid tumours, including prostate, breast, and pancreatic cancers. It aims to find a safe dose and see how it works, either alone or with another drug called Olaparib, in patients whose tumours have a specific genetic weakness.
United States · Spain · United Kingdom - recruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
United States · Canada · China - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
This study is testing a new drug, BLU-222, for people with certain advanced cancers, including breast, ovarian, and stomach cancers. It aims to see how safe the drug is, how it moves through the body, and if it helps shrink tumors, both on its own and with other treatments.
France · Italy · Belgium - active not recruitingPHASE1
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is testing a new cancer medicine, botensilimab, sometimes with another drug, balstilimab. It's for people with advanced cancers that haven't responded to other treatments. Doctors want to see if it's safe, how it works, and find the best dose.
United States · United Kingdom - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE1
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study is testing a new cell therapy called ZI-MA4-1 for certain advanced cancers like ovarian, lung, and head and neck cancer. It's the first time this treatment designed to fight cancer will be given to people, aiming to see if it's safe and how well it works.
United Kingdom - recruitingPHASE1, PHASE2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
This study is testing a new drug, BI-1808, by itself and with another medicine, pembrolizumab (Keytruda®), for people with advanced cancers. The goal is to see how safe the new drug is, what side effects it causes, and find the right dose for future studies.
United States · Denmark · Hungary - ongoing, recruitingTherapeutic exploratory (Phase II)
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer
This study compares two types of body scans (FAPI PET/CT and FDG PET/CT) to see which is better at finding and monitoring ovarian cancer. It aims to improve how doctors understand the cancer's spread and track treatment results.
Denmark - recruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
United States · Argentina · Australia - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
United States · Argentina · Australia - recruitingPHASE2
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
This study is for women with ovarian cancer that has come back, specifically a type that has responded well to chemotherapy in the past. It's looking at a new way to give carboplatin, a common chemotherapy drug, to see if it can work better and with fewer side effects.
United Kingdom - recruitingPHASE2
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
This study is testing a new treatment called Radspherin for advanced ovarian, fallopian tube, or peritoneal cancers. It aims to see how well it works and if it's safe when given with standard chemotherapy and surgery for people whose cancer is suitable for this combined approach.
United States · Belgium · Italy - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - recruitingPHASE2
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study is looking into a new treatment called INCB123667 for women with ovarian cancer that has come back or grown despite platinum-based chemotherapy. Researchers want to see if this treatment is safe and effective, especially for cancers with high levels of a protein called Cyclin E1.
United States · Australia · Belgium - recruitingPHASE3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This study looks at a new drug, Trastuzumab Deruxtecan, combined with an existing treatment, Bevacizumab, for a type of advanced ovarian cancer. It aims to see if this combination works better than Bevacizumab alone after initial chemotherapy.
United States · Australia · Austria - active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
United States · Australia · Belgium - active not recruitingPHASE3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
This study is looking at a new treatment for certain types of ovarian, fallopian tube, or peritoneal cancer that have returned after initial treatment. It compares a new drug, mirvetuximab soravtansine, given with bevacizumab, against bevacizumab alone, to see if the new combination can keep the cancer away for longer.
United States · Argentina · Australia - recruitingNA
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
This study looks at a blood test (Marsden360 ctDNA) for people with certain cancers. It checks if the test helps doctors find the best treatments or clinical trials, and if it makes personalised cancer care better within the NHS.
United Kingdom - recruitingPHASE1
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This study is testing a new experimental vaccine, CryptiVax-1001, for advanced ovarian cancer. It aims to see if the vaccine is safe and if it can help stop the cancer from coming back after standard treatments. This is the first time it’s being used in patients.
United Kingdom - active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
United States · Belgium · Bulgaria - active not recruitingPHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.
United States · Australia · Belgium - recruitingPHASE3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study compares a new medicine, INCB123667, with standard chemotherapy for women with ovarian cancer that has grown despite platinum-based treatment and shows specific genetic changes. It aims to see if the new drug works better than current options.
United States · Australia · Belgium - active not recruitingPHASE2
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
This study is looking at a new way to treat advanced ovarian cancer. It combines a drug called olaparib with standard chemotherapy (carboplatin and paclitaxel) to see if it works better and is safe compared to chemotherapy alone.
United States · Australia · Belgium - active not recruitingPHASE2
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This study looks at giving olaparib, a new drug, before surgery and chemotherapy for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It aims to see if it can shrink tumours and improve outcomes.
Canada · New Zealand · Spain - recruitingPHASE1, PHASE2
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
This study is testing a new drug, TUB-040, for ovarian cancer and a type of lung cancer (non-small cell lung cancer) when standard treatments haven't worked. It checks how safe it is, how it moves in the body, and if it helps shrink tumours. The study aims to find the best dose.
United States · Belgium · Germany - active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
United States · Canada - recruiting
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
This study looks at how cells in ovarian cancer ascites (fluid build-up) use energy. Researchers will give a special, safe form of sugar ([U-13C]glucose) to patients undergoing fluid drainage. This helps them understand cancer and immune cell activity to find better ways to treat this condition.
Canada - recruitingNA
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
This study looks at a new digital tool called GA-Mainstream. It helps people with certain cancers like breast, ovarian, and colon cancer understand genetic testing better. The goal is to make sure patients feel informed and supported while getting tested for genes that can affect their cancer treatment.
Canada - recruitingNA
Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy
This study looks at blood samples from women with BRCA-mutated ovarian cancer receiving PARP inhibitor treatment. We're searching for specific gene changes in their blood to help identify early signs of the cancer returning, allowing for closer monitoring.
France - recruiting
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
This study is developing new blood tests for early cancer detection and to monitor how well treatment is working. It uses artificial intelligence to look at tiny particles in blood samples from people with various cancers and healthy volunteers.
Argentina · Nigeria · United Kingdom - recruiting
Ovarian Cancer Radiomics Approach in CT Led Evaluation
This study uses a new computer method, called radiomics, to analyse CT scans of ovarian cancer. It aims to see if this detailed scan analysis can help doctors plan more personalised treatment and understand the cancer better, potentially leading to new treatments.
United Kingdom - recruiting
Cancer Loyalty Card Study 2 (CLOCS-2)
This study looks at shopping habits using loyalty card data from Tesco or Boots to see if certain purchases might hint at cancer earlier. It aims to help doctors diagnose pancreatic, bowel, oesophageal, stomach, liver, bladder, womb, vulval, and ovarian cancers sooner.
United Kingdom - recruitingPHASE1, PHASE2
Trial of THEO-260 in Ovarian Cancer Patients
This study is testing a new treatment, THEO-260, for advanced ovarian cancer. It's looking for a safe dose and early signs that it can shrink tumours. Only women aged 18 and over with certain types of ovarian cancer who haven't responded to previous treatments can take part.
Spain · United Kingdom - recruitingPHASE1
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
This study is testing a new cancer medicine, OVM-200, for the first time in people. It involves up to 52 patients with prostate, lung, or ovarian cancer to check if it's safe and how well it works. It's given as an injection under the skin.
United Kingdom - recruitingNA
Feasibility of CALM in Patients With Ovarian Cancer
This study looks at a therapy called CALM for people with ovarian cancer. It explores if CALM is helpful and easy to offer soon after diagnosis or if the cancer comes back, and if it can help with stress.
Canada - recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
This study looks at how new cancer treatments affect daily life for people with long-term cancer. It aims to understand how to best support them while they are on these treatments, often for many months or years.
Canada - authorisedTherapeutic exploratory (Phase II)
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.
This study is looking at new ways to treat advanced ovarian cancer that has come back. It tests combinations of new drugs, olaparib, durvalumab, and a vaccine called UV1, to see if they can stop the cancer from growing for longer in patients whose cancer does not have a specific BRCA gene change.
Netherlands · Finland · Norway - active not recruitingPHASE1
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study is testing a new cell therapy for certain cancers that have a specific protein. It aims to see if it's safe and how well people tolerate it. The therapy uses your own modified cells to fight the cancer. Some participants will also receive a small amount of radiation.
United States · Canada - active not recruitingPHASE2
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
This study is for women with ovarian cancer that has come back after treatment with certain drugs (PARP inhibitors). It's looking at new combinations of medicines (tuvusertib with niraparib or lartesertib) to see how well they work and if they are safe.
United States · Australia · Belgium - recruiting
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
This study aims to create a tool to predict how well ovarian cancer patients will respond to chemotherapy. It uses samples from surgery and tracks their treatment to help doctors choose the best personal treatment plan.
United Kingdom - recruiting
Clinical Pre-screening Protocol for Ovarian Cancer
This study looks at your ovarian cancer tissue to see if a special test can predict which cancer drugs might work best for you. It helps doctors understand how effective past treatments were and guide future choices.
United States · United Kingdom - recruitingNA
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
This study looks at a new way to lower ovarian cancer risk in women with certain gene changes. Instead of removing both ovaries and fallopian tubes at once, it explores removing only the fallopian tubes first, and the ovaries later, to delay menopause and its effects. We want to see if this new approach is safe and effective.
United States · Australia · Austria - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE3
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
This study looks at a new drug, oregovomab, combined with standard chemotherapy for women with advanced ovarian cancer after surgery. Researchers want to see if this combination works better and is safe compared to chemotherapy alone.
United States · Argentina · Belgium - recruitingPHASE3
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
This study compares two ways to treat advanced ovarian cancer: standard chemotherapy plus a medicine called niraparib, versus standard chemotherapy plus two medicines, bevacizumab and niraparib. It aims to see which treatment works best to control the cancer.
Germany - recruiting
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
This study looks for clues in your spit to help diagnose common gynaecological problems like endometriosis, ovarian cysts, and cancers. It aims to find new ways to spot these conditions by examining special genetic material (RNA) in saliva.
France - active not recruitingPHASE2
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
This study is for women aged 18-75 with a certain type of ovarian cancer. It tests a new treatment, ADP-A2M4CD8, alone or with nivolumab, to see how well it works and if it's safe.
United States · Canada · France - recruitingPHASE2
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
This study looks at different ways to give a drug called niraparib to women with advanced ovarian cancer. It aims to find out if changing the dose helps reduce side effects while still being an effective treatment after chemotherapy.
Canada